2011
DOI: 10.1007/s11239-011-0667-5
|View full text |Cite
|
Sign up to set email alerts
|

P2Y12 platelet inhibition in clinical practice

Abstract: Platelet adhesion, activation and aggregation play a pivotal role in atherothrombosis. Intracoronary atherothrombosis is the most common cause of the development of acute coronary syndrome (ACS), and plays a central role in complications occurring around percutaneous coronary intervention (PCI) including recurrent ACS, procedure-related myocardial infarction or stent thrombosis. Inhibition of platelet aggregation by medical treatment impairs formation and progression of thrombotic processes and is therefore of… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
67
0
1

Year Published

2012
2012
2024
2024

Publication Types

Select...
6
3
1

Relationship

1
9

Authors

Journals

citations
Cited by 102 publications
(69 citation statements)
references
References 65 publications
(68 reference statements)
0
67
0
1
Order By: Relevance
“…3 However, these drugs are also known to cause a significant increase in the rate of potentially detrimental bleeding complications. [4][5][6] An alternative therapeutic strategy to decrease ADP-induced platelet activation is the administration of a soluble form of CD39 (solCD39), an ecto-nucleoside triphosphate diphosphohydrolase, 7 which is constitutively expressed on endothelial cells and is described as a major physiological mechanism to maintain blood fluidity. [8][9][10][11] CD39 works by hydrolyzing ADP rather than by inhibition of platelet ADP receptors.…”
Section: Introductionmentioning
confidence: 99%
“…3 However, these drugs are also known to cause a significant increase in the rate of potentially detrimental bleeding complications. [4][5][6] An alternative therapeutic strategy to decrease ADP-induced platelet activation is the administration of a soluble form of CD39 (solCD39), an ecto-nucleoside triphosphate diphosphohydrolase, 7 which is constitutively expressed on endothelial cells and is described as a major physiological mechanism to maintain blood fluidity. [8][9][10][11] CD39 works by hydrolyzing ADP rather than by inhibition of platelet ADP receptors.…”
Section: Introductionmentioning
confidence: 99%
“…In case series of simultaneous HCR (CABG directly followed by PCI), a loading dose of clopidogrel (300 or 600 mg) is given either directly before surgery in the holding area [17], after LIMA insertion [28, 29], or after PCI is completed [17, 30, 31]. Interestingly, although maximal inhibition of platelet aggregation occurs only after a couple of hours [32], meaning there is incomplete platelet inhibition at the time of procedure, the reported rates of acute stent thrombosis are low (0% to 7%). Some authors suggest that in procedures performed with cardiopulmonary bypass, the use of cardiopulmonary bypass may be protective against the risk of stent thrombosis [33].…”
Section: Methodsmentioning
confidence: 99%
“…Недостатками являются возможность острых коронарных со-бытий в бассейнах нереваскуляризированных ОА и ПКА при проведении первого этапа, а также воз-можность неуспешного последующего ЧКВ при сложных техниках стентирования, риск рестеноза и тромбоза стента. При неуспешном ЧКВ возни-кает вопрос о необходимости повторной прямой реваскуляризации через срединную стернотомию [23,[43][44][45][46][47].…”
Section: в и ганюков р с тарасов и дрunclassified